The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL)

  • Katarzyna Romejko
    Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, 128 Szaserów Street, 04-141 Warsaw, Poland
  • Magdalena Markowska
    Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, 128 Szaserów Street, 04-141 Warsaw, Poland
  • Stanisław Niemczyk
    Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine—National Research Institute, 128 Szaserów Street, 04-141 Warsaw, Poland

説明

<jats:p>Neutrophil gelatinase-associated lipocalin (NGAL) is a 25-kDa protein that is secreted mostly by immune cells such as neutrophils, macrophages, and dendritic cells. Its production is stimulated in response to inflammation. The concentrations of NGAL can be measured in plasma, urine, and biological fluids such as peritoneal effluent. NGAL is known mainly as a biomarker of acute kidney injury and is released after tubular damage and during renal regeneration processes. NGAL is also elevated in chronic kidney disease and dialysis patients. It may play a role as a predictor of the progression of renal function decreases with complications and mortality due to kidney failure. NGAL is also useful in the diagnostic processes of cardiovascular diseases. It is highly expressed in injured heart tissue and atherosclerostic plaque; its serum concentrations correlate with the severity of heart failure and coronary artery disease. NGAL increases inflammatory states and its levels rise in arterial hypertension, obesity, diabetes, and metabolic complications such as insulin resistance, and is also involved in carcinogenesis. In this review, we present the current knowledge on NGAL and its involvement in different pathologies, especially its role in renal and cardiovascular diseases.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ